echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Clin Transl Med: First discovery of a gradual freezing compound

    Clin Transl Med: First discovery of a gradual freezing compound

    • Last Update: 2021-03-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that quickly paralyzes victims.


    Scientists at Northwestern University have discovered for the first time a compound that eliminates the continued degeneration of upper motor neurons.


    At first, Silverman, a professor of chemistry at Nishimoto University, discovered a compound NU-9 that can reduce protein misfolding in key cell lines.


    The upper motor neuron is the commander-in-chief of brain movement.


    In ALS, motor-initiating nerve cells in the brain (upper motor neurons) and muscles in the spinal cord control nerve cells (lower motor neurons) to die.


    In ALS, motor-initiating nerve cells in the brain (upper motor neurons) and muscles in the spinal cord control nerve cells (lower motor neurons) to die.


    NU-9 treatment can improve the ultrastructural integrity of mitochondria and upper motor neurons ( UMNs ) and endoplasmic reticulum ( ER )

    NU-9 treatment can improve the ultrastructural integrity of mitochondria and upper motor neurons ( UMNs ) and endoplasmic reticulum ( ER )

    NU-9 treatment can improve the cellular structural integrity of the disintegration of the root tip dendrites of upper limb motor neurons ( UMN )

    NU-9 treatment can improve the cellular structural integrity of the disintegration of the root tip dendrites of upper limb motor neurons ( UMN )

    NU - 9 treatment can reduce the degeneration of UMN 's upper motor neuron ( UMN ) that is caused by SOD1 in vivo toxic misfolding

    NU - 9 treatment can reduce the degeneration of upper motor neuron ( UMN ) of UMN that is caused by SOD1 in vivo toxic misfolding

    Research and analysis show that NU-9 has similar drug-like pharmacokinetic properties, can improve the structural integrity of mitochondria and ER, reduce the level of mSOD1, stabilize the degraded UMN apical dendrites, and improve the exercise behavior measured by the thread-hanging test.


    The results showed that the mechanism-centric and cell-based drug discovery method not only solved the key cell defect that caused UMN loss, but also discovered NU-9, the first compound to improve the health of diseased UMNs.


    Mechanism-centric and cell-based drug discovery methods not only solve the key cell defects that lead to UMN loss, but also discover NU-9, which is the first compound to improve the health of diseased UMNs, mechanism-centric and cell-based The drug discovery method not only solved the key cell defect that caused the loss of UMN, but also discovered NU-9, the first compound to improve the health of diseased UMNs.


    Hande Ozdinler, associate professor of neurology at Northwestern University School of Medicine, said that even though upper motor neurons are responsible for the initiation and regulation of exercise, their degeneration is an early event of ALS, but so far, there is no treatment plan to improve their health.


    In fact, the NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: protein misfolding and protein clumps in the cell .


    NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: protein misfolding and protein clumps in the cell NU-9 compound solves two important factors that cause upper motor neuron disease in ALS: Protein misfolding and protein clumps in cells

    After NU-9 was given, both mitochondria and endoplasmic reticulum began to restore their health and integrity, thereby improving the health of neurons.


    The scientists next conducted experiments to reveal how and why the diseased upper motor neurons recovered health.


    Original source:

    Barış Genç, Mukesh Gautam, Öge Gözütok, Ina Dervishi, Santana Sanchez, Gashaw M.


    DOI:doi.
    org/10.
    1002/ctm2.
    336">10.
    1002/ctm2.
    336 10.
    1002/ctm2.
    336 leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.